News

Trevi Therapeutics to Share Financial Insights and Updates

Trevi Therapeutics to Share Financial Insights and Updates

Trevi Therapeutics Announces Upcoming Financial Conference

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a dedicated clinical-stage biopharmaceutical entity, is all set to communicate its financial outcomes and provide critical updates. The company specializes in advancing its leading therapy, Haduvio™ (oral nalbuphine ER), aimed at treating chronic cough linked with idiopathic pulmonary fibrosis (IPF) and other related conditions.

Conference Call Details

Management has arranged a conference call along with a live audio webcast that will occur at 4:30 p.m. ET. This event is designed to highlight the financial accomplishments for the quarter ending June 30, and share essential corporate developments. Interested individuals can participate by calling (877) 870 4263, with international callers reaching out to (412) 317 0790. Joining the call requires no access code, making it straightforward for stakeholders to engage.

Understanding Haduvio and Its Impact

Haduvio, currently being developed by Trevi Therapeutics, has shown promising results in clinical trials. It is noteworthy as the first investigational therapy to demonstrate substantial effectiveness in diminishing cough frequency among patients suffering from chronic cough conditions, specifically those with IPF. Utilizing a unique mechanism as both a kappa agonist and a mu antagonist, Haduvio targets the opioid receptors influencing the cough reflex.

Chronic Cough: A Growing Concern

Chronic cough presents a significant health challenge, particularly for patients grappling with IPF, where up to 85% report experiencing this taxing symptom. In the United States alone, around 150,000 individuals contend with IPF, leading to frustrating coughing episodes up to 1,500 times per day. This relentless cough not only exacerbates the patients' existing condition but may also lead to severe complications like a heightened probability of disease progression or requiring lung transplants.

Navigating the Challenges of Refractory Chronic Cough

Refractory chronic cough (RCC) remains a critical issue as it currently lacks approved treatments within the U.S. This persistent cough continues for over eight weeks, despite therapies aimed at underlying ailments such as asthma or GERD. Affecting approximately 2-3 million people in the U.S., RCC is primarily driven by heightened sensitivity of the cough reflex, leading to a range of distressing side effects and notable social and economic strains.

The Future of Haduvio

Trevi is progressing towards establishing Haduvio as a trademark for its oral nalbuphine ER therapy. However, it’s important to clarify that the safety and efficacy of Haduvio are still under evaluation and have yet to be confirmed by any regulatory body.

Expanding Awareness and Future Prospects

As part of their mission, Trevi Therapeutics aims to spread awareness about chronic cough, an ailment that heavily influences patients' lives. They aim to not only improve clinical outcomes but also enhance the overall quality of life for those afflicted.

The company encourages interested parties to check the official Trevi Therapeutics website for detailed information. Additionally, stakeholders can follow their progress and updates on various social media platforms, staying connected with the ongoing journey towards addressing these health challenges.

Frequently Asked Questions

1. What is the purpose of the upcoming conference call?

The conference call will focus on discussing the financial results and corporate updates of Trevi Therapeutics for the most recent quarter.

2. What is Haduvio and how does it work?

Haduvio is an investigational therapy currently in development for managing chronic cough, acting as both a kappa agonist and a mu antagonist, targeting cough reflex pathways.

3. What are the statistics regarding patients affected by chronic cough?

It is estimated that chronic cough affects up to 85% of IPF patients, with approximately 150,000 individuals suffering from IPF in the U.S.

4. Is there an approved treatment for refractory chronic cough?

As of now, there are no approved treatments for refractory chronic cough in the U.S., which poses significant challenges for affected individuals.

5. How can I stay updated on Trevi Therapeutics' progress?

Interested individuals should visit the Trevi Therapeutics website and follow them on social media platforms to receive the latest news and updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 120

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 65

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 46

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 100

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 143

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 139

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 75

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading

Top 5 Most Recently Viewed Articles

Twist Bioscience Set to Showcase Innovations at J.P. Morgan Event

Updated Category News Views 105

Twist Bioscience to Present at Renowned Healthcare Conference Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in the synthetic biology and genomics field, has announced an upcoming presentation at the annual J.P. Morgan Healthcare Conference. This significant event is slated for January, and it serves as a vital platform for the company to showcase its...

Continue Reading
Leidos Secures Major NSA Contract Worth $390 Million

Updated Category News Views 154

Leidos Wins $390 Million NSA Signals Intelligence Contract Leidos, a prominent player in the defense and technology sectors, has recently secured a significant contract to enhance the capabilities of the National Security Agency (NSA) in the field of signals intelligence (SIGINT). This contract, valued at $390 million, will span an initial year with four additional...

Continue Reading
Devin Shanahan's Strategic Innovations in Global Trade Adaptation

Updated Category News Views 165

Adapting to Global Trade Challenges In a rapidly changing trade landscape, Devin Shanahan, co-founder of the innovative consumer brand Funtazma, is leading thoughtful changes in supply chain management due to the growing impact of U.S.-China trade tensions. With a wealth of experience in scaling consumer brands through global sourcing, Shanahan has been pivotal in guiding...

Continue Reading
Animal Nutrition Chemicals Market Insights and Growth Prospects

Updated Category News Views 185

Animal Nutrition Chemicals Market Overview The rapidly evolving animal nutrition chemicals market is poised for remarkable growth. As the need for high-quality and nutritious animal feed continues to escalate, this sector is likely to see significant changes and expansion. Comprehensive analyses reveal a bright future as industry players adapt to shifting demands and...

Continue Reading
Investors Ensnared in Orthofix Securities Fraud Case Seek Justice

Updated Category News Views 49

Understanding the Orthofix Securities Fraud Case Recently, investors in Orthofix Medical Inc. were informed about a serious legal action involving alleged securities fraud. The Schall Law Firm, which advocates for shareholder rights, is leading a class action lawsuit that addresses the alleged missteps by Orthofix during a specific time frame. It’s important for...

Continue Reading